Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novel Anti-Infectives

This article was originally published in Start Up

Executive Summary

The introduction of new anti-infective drugs has not kept pace with the ability of bacteria to resist and render ineffective just about all antibiotics developed since the late 1920's. Influenza, hepatitis, pneumonia, meningitis, AIDS, tuberculosis and plenty of other infections are killing people, and not just in third world countries. In the US, infection is the third leading cause of death, behind heart disease and cancer. Since the mid-90's, the seriousness of the bacterial drug resistance problem has caused pharmaceutical companies to redouble their R&D efforts. And the problem has spawned a new industry of start-ups as well. Elitra Pharmaceuticals and Arrow Therapeutics hope to add to the anti-infective armamentarium with drugs that attack targets necessary for bacterial growth and survival. EluSys Therapeutics has an immunological approach, taking advantage of bispecific antibodies to clear toxins and pathogens from the bloodstream. Paratek Pharmaceuticals has taken a different approach. It's attacking the mechanism of resistance directly.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts